ReviewFrontiers in medicine2021
Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Prediction models for mortality in patients with acute on chronic liver failure: systematic review and critical appraisal.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure: a systematic review and meta-analysis of randomized controlled clinical trials.Stem cell research & therapy · 2025Pooled it
- Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- The Improvement Effects ofNutrients · 2025Trial
- Hepatic Encephalopathy Severity and Mortality Risk Stratification in Alcohol-Related Acute-on-Chronic Liver Failure.Diagnostics (Basel, Switzerland) · 2026Article
- Development and internal validation of the SCAN score: a pragmatic bedside tool for early prediction of spontaneous bacterial peritonitis in patients with cirrhosis and ascites.Clinical and experimental hepatology · 2026Article
- Real-world evidence on predictors of antimicrobial resistance among patients with chronic liver disease.Frontiers in medicine · 2026Article
- RAC1 as a novel therapeutic target for acute liver failure.JHEP reports : innovation in hepatology · 2025Article
- Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis.Infectious diseases and therapy · 2025Article
- Neutrophil percentage-to-albumin ratio as a novel predictor of mortality in HBV-Related acute-on-chronic liver failure.Biomarkers in medicine · 2025Article
- Interprofessional Therapeutic Drug Monitoring of Piperacillin/Tazobactam Enhances Care for Patients with Acute-on-Chronic Liver Failure in the ICU: A Retrospective Observational Pilot Study.Antibiotics (Basel, Switzerland) · 2025Article
- A nomogram model based on tumor necrosis factor-like ligand 1A(TL1A) and death receptor-3(DR3) promoter methylation for predicting 90-day prognosis in patients with HBV-associated acute-on-chronic liver failure.Frontiers in molecular biosciences · 2025Article
- [Research progress on the role and mechanism of PANoptosis in liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Mesenchymal stromal cell-derived extracellular vesicles therapy openings new translational challenges in immunomodulating acute liver inflammation.Journal of translational medicine · 2024Review
- Article
- [Experimental study on the inhibition of the NLRP3 signaling pathway with Shengsan Jiedu Huayu decoction to alleviate inflammatory injury in rats with acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Acute-on-chronic liver failure: a retrospective review of cases at a transplantation center in Brazil.Acta cirurgica brasileira · 2024Article
- Acute-on-Chronic Liver Failure: Causes, Clinical Parameters, and Predictors of Mortality.Cureus · 2024Article
- Changes in TNF-α, IL-33, and MIP-1α before and after artificial liver support treatment and their prognostic value.American journal of translational research · 2024Article
- Prognostic Value of Platelet-to-Monocyte Ratio for Mortality in HBV-Related Acute-on-Chronic Liver Failure.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute-on-chronic liver failure (ACLF) is a multifaceted condition with poor treatment options and high short-term mortality. ACLF can develop in patients with or without liver cirrhosis, where patients with decompensated cirrhosis display a higher risk of short-term mortality. Pathophysiological mechanisms include systemic inflammation due to bacterial and fungal infections and acute hepatic insult with drug, alcohol, and viral hepatitis. Cryptogenic factors also contribute to the development of ACLF. The clinical outcome of patients with ACLF gets further complicated by the occurrence of variceal hemorrhage, hepatorenal syndrome, hepatic encephalopathy, and systemic immune dysfunction. Regardless of the better understanding of pathophysiological mechanisms, no specific and definitive treatment is available except for liver transplantation. The recent approach of regenerative medicine using mesenchymal stem cells (MSCs) could be advantageous for the treatment of ACLF as these cells can downregulate inflammatory response by inducing antiinflammatory events and prevent hepatic damage and fibrosis by inhibiting hepatic stellate cell activation and collagen synthesis. Moreover, MSCs are involved in tissue repair by the process of liver regeneration. Considering the broad therapeutic potential of MSCs, it can serve as an alternative treatment to liver transplant in the near future, if promising results are achieved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.